BackBristol Myers Squibb Partners with China's Hengrui Pharma in Multi-Billion Dollar Deal

NACHRICHT

CNBC15.05.2026Business

Bristol Myers Squibb Partners with China's Hengrui Pharma in Multi-Billion Dollar Deal

Bristol Myers Squibb Hengrui Pharma US-China Pharma Collaboration

Auf einen Blick

Bristol Myers Squibb partners with Hengrui Pharma to develop 12 experimental drugs, marking a significant, reciprocal collaboration that could signal increased U.S. pharmaceutical development in China for faster, cheaper drug creation.

KI-generierte Zusammenfassung

Schriftgröße

Read the full article on CNBC

Ähnliche Meldungen

Mehr zu diesem ThemaBristol Myers Squibb

In Entwicklung·1 sa önce

Gas Prices Could Rise Amid Renewed Tensions with Iran

Gas prices may increase as President Trump signals the end of a U.S.-Iran ceasefire, potentially pushing the national average towards $4 a gallon. Financial planners advise drivers to review budgets and cut discretionary spending.

CNBC

In Entwicklung·1 sa önce

Luxshare Precision Industry's Hong Kong IPO Falls on Debut

Luxshare Precision Industry, a major Apple supplier, saw its shares end lower on their Hong Kong trading debut Thursday, despite raising $3.09 billion in its IPO, the largest this year. The stock closed down 1.55% after opening lower.

CNBC

In Entwicklung·1 sa önce

South Korea's Kospi Enters Bear Territory Amid AI Skepticism and Market Concentration

South Korea's Kospi stock index has fallen into bear market territory, down over 20% from its record high, due to global investor skepticism about AI plays and extreme market concentration in chipmakers Samsung Electronics and SK Hynix.

CNBC

Dringend·2 sa önce

AstraZeneca Shares Tumble After Heart Disease Drug Trial Fails

AstraZeneca's stock dropped nearly 9% after its experimental heart disease drug, Wainua, failed to meet its primary target in a late-stage clinical trial. The drug, intended for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), did not significantly reduce deaths or heart emergencies compared to a placebo.

CNBC

In Entwicklung·4 sa önce

Luxshare Precision Industry Shares Dip on Hong Kong Debut After Record IPO

Luxshare Precision Industry's shares dropped over 5% in their Hong Kong trading debut Thursday, following its $3.09 billion IPO, the largest this year. The Apple supplier, already listed in Shenzhen, priced shares at HK$63.28, with the stock trading at HK$60 early on.

CNBC

In Entwicklung·5 sa önce

Temasek Still Avoiding Crypto After FTX Loss, Focuses on AI and Europe

Temasek Global Investments president Nagi Hamiyeh stated crypto investment remains off-limits due to regulatory uncertainty and the company's substantial loss from FTX. The firm is increasing its AI exposure and investing in European luxury and industrials.

CNBC

Mehr zu diesem ThemaBristol Myers Squibb

Bristol Myers Squibb Partners with China's Hengrui Pharma in Multi-Billion Dollar Deal

Auf einen Blick

Verwandte Themen

Ähnliche Meldungen

Gas Prices Could Rise Amid Renewed Tensions with Iran

Luxshare Precision Industry's Hong Kong IPO Falls on Debut

South Korea's Kospi Enters Bear Territory Amid AI Skepticism and Market Concentration

AstraZeneca Shares Tumble After Heart Disease Drug Trial Fails

Luxshare Precision Industry Shares Dip on Hong Kong Debut After Record IPO

Temasek Still Avoiding Crypto After FTX Loss, Focuses on AI and Europe